Convert Pharmaceuticals
Convert Pharmaceuticals is a pioneering platform company specializing in the development of prodrugs that remain inert until they reach the tumor site, transforming into powerful anti-cancer agents within the tumor microenvironment. They focus on targeting tumor hypoxia, a major contributor to cancer treatment resistance, and develop hypoxia-activated prodrugs to improve cancer therapy outcomes.
Industries
Nr. of Employees
small (1-50)
Convert Pharmaceuticals
Patents
Products
Lead hypoxia-activated DNA-alkylating clinical candidate (lead molecule)
A next-generation hypoxia-activated DNA-alkylating prodrug designed for selective activation in hypoxic tumor regions; optimized for improved pharmacokinetic properties, potential oral bioavailability, and reduced metabolic liabilities.
Lead hypoxia-activated DNA-alkylating clinical candidate (lead molecule)
A next-generation hypoxia-activated DNA-alkylating prodrug designed for selective activation in hypoxic tumor regions; optimized for improved pharmacokinetic properties, potential oral bioavailability, and reduced metabolic liabilities.
Services
Operational coordination and management of Phase I and Phase IIa/b oncology trials, including study start-up, monitoring of trial conduct, and close-out activities.
Development and application of biomarkers to detect tumor hypoxia and stratify patients for clinical studies.
Conduct of in vivo efficacy studies across panels of tumor xenograft models to evaluate antitumor activity and pharmacodynamic relationships.
Operational coordination and management of Phase I and Phase IIa/b oncology trials, including study start-up, monitoring of trial conduct, and close-out activities.
Development and application of biomarkers to detect tumor hypoxia and stratify patients for clinical studies.
Conduct of in vivo efficacy studies across panels of tumor xenograft models to evaluate antitumor activity and pharmacodynamic relationships.
Expertise Areas
- Hypoxia-targeted oncology therapeutics
- Biomarker discovery and validation
- Preclinical pharmacology and efficacy testing
- Early-phase clinical trial management (Phase I–IIa/b)
Key Technologies
- Hypoxia-activated prodrug design
- DNA alkylating agent chemistry
- In vivo tumor xenograft models
- Biomarker assays for tumor hypoxia
News & Updates
Convert Pharmaceuticals secured a €2.5 million grant from the European Innovation Council (EIC) Accelerator program, supporting its ongoing clinical trials.
Research supported by Yale School of Medicine and other institutions validates the strategy of advancing cancer treatment through hypoxia-targeted therapies, aligning with Convert Pharmaceuticals’ approach.
An article explaining how hypoxia fuels cancer, past failures in targeting it, and how Convert Pharmaceuticals aims to turn hypoxia into a weapon against cancer.
Convert Pharmaceuticals secured a €2.5 million grant from the European Innovation Council (EIC) Accelerator program, supporting its ongoing clinical trials.
Research supported by Yale School of Medicine and other institutions validates the strategy of advancing cancer treatment through hypoxia-targeted therapies, aligning with Convert Pharmaceuticals’ approach.
An article explaining how hypoxia fuels cancer, past failures in targeting it, and how Convert Pharmaceuticals aims to turn hypoxia into a weapon against cancer.